April 25, 2024
Stocks & Bonds
[EQUITIES] ‘ChongKunDang to remain on upturn’
[THE INVESTOR] ChongKunDang Pharmaceutical has posted an earnings surprise and will continue to grow, said HMC Investment Securities on April 25.
 |
Its overall operating costs have declined, while it is in final stages of developing competitive products, including CKD-519, a hyperlipidemia treatment that is in the second phase of clinical trials in Australia, explained analyst Kang Yang-gu.
The prospects for technology export of core products are also positive, the analyst said.
By Hwang You-mee (glamazon@heraldcorp.com)
![[From the Scene] KG Mobility poised to take next leap](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/24/20240424050621_0.jpg)
